Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

74.33
Delayed Data
As of Feb 05
 -0.73 / -0.97%
Today’s Change
73.97
Today|||52-Week Range
106.84
-13.61%
Year-to-Date
Why Ophthotech Corporation Shares Tumbled 31% in January
Feb 06 / MotleyFool.com
Radius (RDUS) Collaborates With Novartis Targeting Cancer
Jan 28 / Zacks.com
ImmunoGen, Inc.'s Earnings Play the Amortization Blues
Feb 04 / MotleyFool.com
Why Incyte's Shares Crashed 12% Today
Jan 28 / MotleyFool.com
Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact
Feb 04 / Zacks.com
Incyte Halts Phase II Jakafi-Stivarga Combination Study
Jan 28 / Zacks.com
3 Value Stocks Near 52-Week Lows Worth Buying
Feb 04 / MotleyFool.com
Novartis (NVS) Lags Q4 Earnings & Revenues, Alcon Down
Jan 28 / Zacks.com
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study
Feb 02 / Zacks.com
Eli Lilly Tops on 4Q Earnings, Revenues, Maintains View
Jan 28 / Zacks.com
Can GlaxoSmithKline (GSK) Q4 Earnings Surprise Estimates?
Feb 01 / Zacks.com
Is Another Big Transformation on the Way for GlaxoSmithKline?
Jan 28 / MotleyFool.com
New Strong Sell Stocks for February 1st
Feb 01 / Zacks.com
Amgen's Biosimilar of AbbVie's Humira under FDA Review
Jan 27 / Zacks.com
Biotech ETFs Hit 52-Week Lows: Time to Buy?
Feb 01 / Zacks.com
Novartis (NVS) Posts Lower-Than-Expected Earnings in Q4
Jan 27 / Zacks.com
Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question
Feb 01 / TheStreet.com
Novartis (NVS) to Report Q4 Earnings: Will It Disappoint?
Jan 25 / Zacks.com
Why Exelixis, Inc. Rocketed Higher on Friday
Jan 29 / MotleyFool.com
Bristol-Myers' Opdivo/Yervoy Combination Expanded in U.S.
Jan 25 / Zacks.com
The 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results
Jan 29 / MotleyFool.com